|
XB--6457939
Papers associated with gabarap (and Disease Ontology)
???pagination.result.count???
???pagination.result.page??? 1
| Sort Newest To Oldest | Sort Oldest To Newest |
referenced by: |
Advancements in the use of xenopus oocytes for modelling neurological disease for novel drug discovery., O'Connor EC, Kambara K, Bertrand D., Expert Opin Drug Discov. February 1, 2024; 19 (2): 173-187.  |
|
GABAA receptor function is enhanced by Interleukin-10 in human epileptogenic gangliogliomas and its effect is counteracted by Interleukin-1β., Ruffolo G, Alfano V, Romagnolo A, Zimmer T, Mills JD, Cifelli P, Gaeta A, Morano A, Anink J, Mühlebner A, Vezzani A, Aronica E, Palma E., Sci Rep. October 26, 2022; 12 (1): 17956.  |
|
Dissecting the Molecular Determinants of GABAA Receptors Current Rundown, a Hallmark of Refractory Human Epilepsy., Cifelli P, Di Angelantonio S, Alfano V, Morano A, De Felice E, Aronica E, Ruffolo G, Palma E., Brain Sci. March 30, 2021; 11 (4):  |
|
Characterization of the GABRB2-Associated Neurodevelopmental Disorders., El Achkar CM, Harrer M, Smith L, Kelly M, Iqbal S, Maljevic S, Niturad CE, Vissers LELM, Poduri A, Yang E, Lal D, Lerche H, Møller RS, Olson HE, GABRB2 Working Group., Ann Neurol. March 1, 2021; 89 (3): 573-586.  |
|
The anticonvulsant zonisamide positively modulates recombinant and native glycine receptors at clinically relevant concentrations., Devenish SO, Winters BL, Anderson LL, Arnold JC, McGregor IS, Vaughan CW, Chebib M, Absalom NL., Neuropharmacology. January 1, 2021; 182 108371. |
|
In vitro and in vivo characterization of Lu AA41178: A novel, brain penetrant, pan-selective Kv7 potassium channel opener with efficacy in preclinical models of epileptic seizures and psychiatric disorders., Grupe M, Bentzen BH, Benned-Jensen T, Nielsen V, Frederiksen K, Jensen HS, Jacobsen AM, Skibsbye L, Sams AG, Grunnet M, Rottländer M, Bastlund JF., Eur J Pharmacol. November 15, 2020; 887 173440. |
|
Rare Diseases of Neurodevelopment: Maintain the Mystery or Use a Dazzling Tool for Investigation? The Case of Rett Syndrome., Ruffolo G, Cifelli P, Miranda-Lourenço C, De Felice E, Limatola C, Sebastião AM, Diógenes MJ, Aronica E, Palma E., Neuroscience. July 15, 2020; 439 146-152. |
|
Differential Coassembly of α1-GABAARs Associated with Epileptic Encephalopathy., Hannan S, Affandi AHB, Minere M, Jones C, Goh P, Warnes G, Popp B, Trollmann R, Nizetic D, Smart TG., J Neurosci. July 15, 2020; 40 (29): 5518-5530. |
|
Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions., Anderson LL, Absalom NL, Abelev SV, Low IK, Doohan PT, Martin LJ, Chebib M, McGregor IS, Arnold JC., Epilepsia. November 1, 2019; 60 (11): 2224-2234.  |
|
Functional genomics of epilepsy-associated mutations in the GABAA receptor subunits reveal that one mutation impairs function and two are catastrophic., Absalom NL, Ahring PK, Liao VW, Balle T, Jiang T, Anderson LL, Arnold JC, McGregor IS, Bowen MT, Chebib M., J Biol Chem. April 12, 2019; 294 (15): 6157-6171.  |
|
A novel GABAergic dysfunction in human Dravet syndrome., Ruffolo G, Cifelli P, Roseti C, Thom M, van Vliet EA, Limatola C, Aronica E, Palma E., Epilepsia. November 1, 2018; 59 (11): 2106-2117. |
|
Rare coding variants in genes encoding GABAA receptors in genetic generalised epilepsies: an exome-based case-control study., May P, Girard S, Harrer M, Bobbili DR, Schubert J, Wolking S, Becker F, Lachance-Touchette P, Meloche C, Gravel M, Niturad CE, Knaus J, De Kovel C, Toliat M, Polvi A, Iacomino M, Guerrero-López R, Baulac S, Marini C, Thiele H, Altmüller J, Jabbari K, Ruppert AK, Jurkowski W, Lal D, Rusconi R, Cestèle S, Terragni B, Coombs ID, Reid CA, Striano P, Caglayan H, Siren A, Everett K, Møller RS, Hjalgrim H, Muhle H, Helbig I, Kunz WS, Weber YG, Weckhuysen S, Jonghe P, Sisodiya SM, Nabbout R, Franceschetti S, Coppola A, Vari MS, Kasteleijn-Nolst Trenité D, Baykan B, Ozbek U, Bebek N, Klein KM, Rosenow F, Nguyen DK, Dubeau F, Carmant L, Lortie A, Desbiens R, Clément JF, Cieuta-Walti C, Sills GJ, Auce P, Francis B, Johnson MR, Marson AG, Berghuis B, Sander JW, Avbersek A, McCormack M, Cavalleri GL, Delanty N, Depondt C, Krenn M, Zimprich F, Peter S, Nikanorova M, Kraaij R, van Rooij J, Balling R, Ikram MA, Uitterlinden AG, Avanzini G, Schorge S, Petrou S, Mantegazza M, Sander T, LeGuern E, Serratosa JM, Koeleman BPC, Palotie A, Lehesjoki AE, Nothnagel M, Nürnberg P, Maljevic S, Zara F, Cossette P, Krause R, Lerche H, Epicure Consortium, EuroEPINOMICS CoGIE Consortium, EpiPGX Consortium., Lancet Neurol. August 1, 2018; 17 (8): 699-708. |
|
Rare GABRA3 variants are associated with epileptic seizures, encephalopathy and dysmorphic features., Niturad CE, Lev D, Kalscheuer VM, Charzewska A, Schubert J, Lerman-Sagie T, Kroes HY, Oegema R, Traverso M, Specchio N, Lassota M, Chelly J, Bennett-Back O, Carmi N, Koffler-Brill T, Iacomino M, Trivisano M, Capovilla G, Striano P, Nawara M, Rzonca S, Fischer U, Bienek M, Jensen C, Hu H, Thiele H, Altmüller J, Krause R, May P, Becker F, EuroEPINOMICS Consortium, Balling R, Biskup S, Haas SA, Nürnberg P, van Gassen KLI, Lerche H, Zara F, Maljevic S, Leshinsky-Silver E., Brain. November 1, 2017; 140 (11): 2879-2894. |
|
Antidepressant, anticonvulsant and antinociceptive effects of 3'-methoxy-6-methylflavone and 3'-hydroxy-6-methylflavone may involve GABAergic mechanisms., Karim N, Khan I, Ahmad N, Umar MN, Gavande N., Pharmacol Rep. October 1, 2017; 69 (5): 1014-1020. |
|
Mutations in GABRB3: From febrile seizures to epileptic encephalopathies., Møller RS, Wuttke TV, Helbig I, Marini C, Johannesen KM, Brilstra EH, Vaher U, Borggraefe I, Talvik I, Talvik T, Kluger G, Francois LL, Lesca G, de Bellescize J, Blichfeldt S, Chatron N, Holert N, Jacobs J, Swinkels M, Betzler C, Syrbe S, Nikanorova M, Myers CT, Larsen LH, Vejzovic S, Pendziwiat M, von Spiczak S, Hopkins S, Dubbs H, Mang Y, Mukhin K, Holthausen H, van Gassen KL, Dahl HA, Tommerup N, Mefford HC, Rubboli G, Guerrini R, Lemke JR, Lerche H, Muhle H, Maljevic S., Neurology. January 31, 2017; 88 (5): 483-492. |
|
Functional aspects of early brain development are preserved in tuberous sclerosis complex (TSC) epileptogenic lesions., Ruffolo G, Iyer A, Cifelli P, Roseti C, Mühlebner A, van Scheppingen J, Scholl T, Hainfellner JA, Feucht M, Krsek P, Zamecnik J, Jansen FE, Spliet WG, Limatola C, Aronica E, Palma E., Neurobiol Dis. November 1, 2016; 95 93-101. |
|
Fragile X mental retardation protein knockdown in the developing Xenopus tadpole optic tectum results in enhanced feedforward inhibition and behavioral deficits., Truszkowski TL, James EJ, Hasan M, Wishard TJ, Liu Z, Pratt KG, Cline HT, Aizenman CD., Neural Dev. August 8, 2016; 11 (1): 14.  |
|
Development of GABAA Receptor Subtype-Selective Imidazobenzodiazepines as Novel Asthma Treatments., Forkuo GS, Guthrie ML, Yuan NY, Nieman AN, Kodali R, Jahan R, Stephen MR, Yocum GT, Treven M, Poe MM, Li G, Yu OB, Hartzler BD, Zahn NM, Ernst M, Emala CW, Stafford DC, Cook JM, Arnold LA., Mol Pharm. June 6, 2016; 13 (6): 2026-38. |
|
Potentiation of Gamma Aminobutyric Acid Receptors (GABAAR) by Ethanol: How Are Inhibitory Receptors Affected?, Förstera B, Castro PA, Moraga-Cid G, Aguayo LG., Front Cell Neurosci. May 6, 2016; 10 114.  |
|
GABAA currents are decreased by IL-1β in epileptogenic tissue of patients with temporal lobe epilepsy: implications for ictogenesis., Roseti C, van Vliet EA, Cifelli P, Ruffolo G, Baayen JC, Di Castro MA, Bertollini C, Limatola C, Aronica E, Vezzani A, Palma E., Neurobiol Dis. October 1, 2015; 82 311-320. |
|
Inhibitory effects of insulin on GABAA currents modulated by the GABAA alpha subunit., Williams DB., J Recept Signal Transduct Res. January 1, 2015; 35 (6): 516-22. |
|
Two different mechanisms of disinhibition produced by GABAA receptor mutations linked to epilepsy in humans., Bianchi MT, Song L, Zhang H, Macdonald RL., J Neurosci. July 1, 2002; 22 (13): 5321-7. |
???pagination.result.page??? 1